RGC director disposes 19,000 stock options to issuer

Regencell Bioscience Holdings Ltd director HUI EVANA YEE WAH reported a disposition of stock options back to the company.

Rhea-AI Filing Summary

Regencell Bioscience Holdings Ltd director HUI EVANA YEE WAH reported a disposition of stock options back to the company. On May 27, 2026, the issuer repurchased options to purchase 19,000 ordinary shares at $15.00 per option under an Option Repurchase Agreement.

The repurchased options had an exercise price of $0.25 per share. Following this issuer disposition, the reporting person is shown with 573,230 shares related to this security, indicating she retains a substantial position after the transaction.

Insider Trade Summary

Disposition: 19,000 shares

Disposition 1 txn

Insider HUI EVANA YEE WAH

Role Director

Type	Security	Shares	Price	Value
Disposition	Stock option (right to purchase)	19,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to purchase) — 573,230 contracts (Direct)

Footnotes (2)

1. F1. The exercise price has given effect to the share split(s) of the Issuer since the date of grant of the option.
2. F2. On May 27, 2026, the Issuer repurchased from the Reporting Person options to purchase 19,000 ordinary shares of the Issuer at a price of $15.00 per option. The aggregate consideration payable to the Reporting Person under the Option Repurchase Agreement is further reduced by the aggregate exercise price of the repurchased options.

Key Figures

Options repurchased: 19,000 options Repurchase price per option: $15.00 per option Option exercise price: $0.25 per share +1 more

4 metrics

Options repurchased 19,000 options Options to purchase ordinary shares repurchased by issuer on May 27, 2026

Repurchase price per option $15.00 per option Consideration paid by issuer for each repurchased option

Option exercise price $0.25 per share Exercise price of the repurchased stock options after share split adjustments

Shares following transaction 573,230 shares Total shares related to this security after the disposition

Key Terms

stock option (right to purchase), Option Repurchase Agreement, exercise price, disposition to issuer

4 terms

stock option (right to purchase) financial

"security_title: Stock option (right to purchase)"

Option Repurchase Agreement financial

"aggregate consideration payable to the Reporting Person under the Option Repurchase Agreement"

exercise price financial

"The exercise price has given effect to the share split(s) of the Issuer"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

disposition to issuer financial

"transaction_action: issuer disposition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RGC director HUI EVANA YEE WAH report?

Director HUI EVANA YEE WAH reported an issuer disposition of stock options. Regencell Bioscience repurchased options to purchase 19,000 ordinary shares from her under an Option Repurchase Agreement, rather than these options being exercised or sold in the open market.

How many Regencell Bioscience (RGC) options were repurchased in this Form 4?

The company repurchased options to purchase 19,000 ordinary shares. These options were previously granted stock options, and the transaction is reported as a disposition to the issuer, meaning the options were returned to the company rather than converted into shares.

What price did Regencell Bioscience pay per option in the RGC Form 4?

Regencell Bioscience agreed to pay $15.00 per option for the repurchase. The footnote explains this price applies to each of the 19,000 options, with the aggregate consideration reduced by the total exercise price that would have been payable on those options.

What was the exercise price of the repurchased RGC stock options?

The repurchased options had an exercise price of $0.25 per ordinary share. A footnote notes that this exercise price reflects share split adjustments since the original grant date, meaning the economic terms were adjusted to account for past share splits.

How many shares does the RGC director hold after this Form 4 transaction?

Following the issuer disposition of options, total shares related to this security are reported as 573,230. This figure shows the director continues to have a sizable position even after returning 19,000 stock options to Regencell Bioscience through the repurchase agreement.

Was the RGC Form 4 transaction an open-market sale of shares?

No, the Form 4 describes an issuer disposition of stock options, not an open-market share sale. The company repurchased options to purchase 19,000 ordinary shares directly from the director under an Option Repurchase Agreement, with specified per‑option consideration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 06:20 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HUI EVANA YEE WAH

(Last) (First) (Middle)

C/O 9/F CHINACHEM LEIGHTON PLAZA

29 LEIGHTON ROAD, CAUSEWAY BAY

(Street)

HONG KONG

(City) (State) (Zip)

CHINA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Regencell Bioscience Holdings Ltd [ RGC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to purchase)	$0.25(1)	05/27/2026		D			19,000	(2)	(2)	Ordinary shares, par value $0.00001	19,000	(2)	573,230	D

Explanation of Responses:

1. The exercise price has given effect to the share split(s) of the Issuer since the date of grant of the option.

2. On May 27, 2026, the Issuer repurchased from the Reporting Person options to purchase 19,000 ordinary shares of the Issuer at a price of $15.00 per option. The aggregate consideration payable to the Reporting Person under the Option Repurchase Agreement is further reduced by the aggregate exercise price of the repurchased options.

	/s/ James Wai Hong Chung, attorney-in-fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)